RU2015119245A - Комбинация - Google Patents

Комбинация Download PDF

Info

Publication number
RU2015119245A
RU2015119245A RU2015119245A RU2015119245A RU2015119245A RU 2015119245 A RU2015119245 A RU 2015119245A RU 2015119245 A RU2015119245 A RU 2015119245A RU 2015119245 A RU2015119245 A RU 2015119245A RU 2015119245 A RU2015119245 A RU 2015119245A
Authority
RU
Russia
Prior art keywords
chloro
methyl
ethyl
amino
combination
Prior art date
Application number
RU2015119245A
Other languages
English (en)
Russian (ru)
Inventor
Тона М. Джилмер
Ракеш Кумар
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2015119245A publication Critical patent/RU2015119245A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
RU2015119245A 2012-10-22 2013-10-21 Комбинация RU2015119245A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261716780P 2012-10-22 2012-10-22
US61/716,780 2012-10-22
PCT/US2013/065827 WO2014066202A1 (en) 2012-10-22 2013-10-21 Combination

Publications (1)

Publication Number Publication Date
RU2015119245A true RU2015119245A (ru) 2016-12-10

Family

ID=50545138

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015119245A RU2015119245A (ru) 2012-10-22 2013-10-21 Комбинация

Country Status (12)

Country Link
US (1) US20150272952A1 (enExample)
EP (1) EP2908815A4 (enExample)
JP (1) JP2015534986A (enExample)
KR (1) KR20150074097A (enExample)
CN (1) CN104902899A (enExample)
AU (1) AU2013334943A1 (enExample)
BR (1) BR112015008924A2 (enExample)
CA (1) CA2889051A1 (enExample)
IN (1) IN2015DN03909A (enExample)
MX (1) MX2015005113A (enExample)
RU (1) RU2015119245A (enExample)
WO (1) WO2014066202A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP2485593B1 (en) * 2009-10-08 2015-01-07 GlaxoSmithKline LLC Combination
WO2011060380A1 (en) * 2009-11-14 2011-05-19 The Regents Of The University Of California Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer
US20130072507A1 (en) * 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy

Also Published As

Publication number Publication date
EP2908815A1 (en) 2015-08-26
AU2013334943A1 (en) 2015-05-14
US20150272952A1 (en) 2015-10-01
CA2889051A1 (en) 2014-05-01
JP2015534986A (ja) 2015-12-07
EP2908815A4 (en) 2016-06-22
KR20150074097A (ko) 2015-07-01
BR112015008924A2 (pt) 2017-07-04
CN104902899A (zh) 2015-09-09
MX2015005113A (es) 2015-10-29
WO2014066202A1 (en) 2014-05-01
IN2015DN03909A (enExample) 2015-10-02

Similar Documents

Publication Publication Date Title
KR102566924B1 (ko) 케모카인 수용체 조절제 및 이의 용도
RU2018105655A (ru) Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
RU2019114963A (ru) Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
JP2007529421A5 (enExample)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2016040288A5 (enExample)
JP2016513737A5 (enExample)
JP6002835B2 (ja) 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
JP2014518544A5 (enExample)
JP2015511609A5 (enExample)
RU2013144571A (ru) Алинзамещенные хиназолины и способы их применения
JP2015512943A5 (enExample)
TWI544920B (zh) Ｎ－羥基－４－｛２－［３－（ｎ，ｎ－二甲基胺基甲基）苯並呋喃－２－基羰基胺基］乙氧基｝苯甲醯胺之新穎投藥法
JP2014534269A5 (enExample)
JP2014507412A5 (enExample)
RU2015119218A (ru) Комбинация
RU2014150860A (ru) Режим дозирования pi-3 киназы
JP2015517523A5 (enExample)
JP2012522841A5 (enExample)
RU2016116789A (ru) Комбинация энзалутамида и афурезертиба для лечения рака
JP2023513655A5 (enExample)
JP2013528215A5 (enExample)
JP5858989B2 (ja) 組合せ
JP2014523426A5 (enExample)
JP2013526579A5 (enExample)

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20161024